Zelnorm--FDA says Risks Outweigh Benefits

Well, the FDA is stepping up to the plate and putting scrutiny of drug companies who spend more on advertisements than research. Novartis, the maker of Zelnorm, a drug prescribed for irritable bowel syndrome (IBS) reluctantly took Zelnorm off the market on Friday, March 30th.

Zelnorm was linked to a statistically significant number of heart attacks, strokes and angina pain. In fact, Novartis even admits that it knew about increased angina pain back in 2002, but the company did not feel it was statistically significant. This recent review of the same data showed differently.

This tidbit is very interesting..."In a 2003 presentation, Thomas Ebeling, chief executive of Novartis's drug division, said that Zelnorm's sales in the United States were closely tied to consumer advertising. 'The weeks we go off the air, the growth flattens. When we restart, you see the growth accelerate again,' Mr. Ebeling said." NYT has the full story.

If you take Zelnorm, contact your doctor immediately for help in getting on a new and safer drug. If you take Zelnorm and suffered a heart attack, stroke or angina pain, contact us to protect your legal rights.


Popular posts from this blog

Safety for Your Family or Corporations?

New Report on Nursing Home Negligence

Supreme Court Knocks Down FDA Preemption